Mutual of America Capital Management LLC Sells 1,558 Shares of Inari Medical, Inc. (NASDAQ:NARI)

Mutual of America Capital Management LLC cut its stake in Inari Medical, Inc. (NASDAQ:NARI) by 4.7% in the fourth quarter, HoldingsChannel.com reports. The fund owned 31,426 shares of the company’s stock after selling 1,558 shares during the period. Mutual of America Capital Management LLC’s holdings in Inari Medical were worth $2,040,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in NARI. Wellington Management Group LLP grew its stake in shares of Inari Medical by 46.8% in the first quarter. Wellington Management Group LLP now owns 4,626,607 shares of the company’s stock worth $419,355,000 after acquiring an additional 1,475,313 shares during the period. Norges Bank bought a new stake in shares of Inari Medical in the fourth quarter worth approximately $73,924,000. Price T Rowe Associates Inc. MD grew its stake in shares of Inari Medical by 132.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,863,816 shares of the company’s stock worth $115,073,000 after acquiring an additional 1,060,839 shares during the period. Morgan Stanley grew its stake in shares of Inari Medical by 400.9% in the fourth quarter. Morgan Stanley now owns 1,273,630 shares of the company’s stock worth $80,952,000 after acquiring an additional 1,019,378 shares during the period. Finally, BlackRock Inc. grew its stake in shares of Inari Medical by 13.0% in the second quarter. BlackRock Inc. now owns 6,385,806 shares of the company’s stock worth $371,271,000 after acquiring an additional 733,738 shares during the period. 90.98% of the stock is currently owned by institutional investors.

Inari Medical Stock Performance

NARI stock opened at $38.59 on Friday. Inari Medical, Inc. has a one year low of $37.92 and a one year high of $71.85. The company’s fifty day moving average price is $46.89 and its 200-day moving average price is $55.25. The company has a market capitalization of $2.24 billion, a PE ratio of -1,286.33 and a beta of 0.84.

Inari Medical (NASDAQ:NARI) last released its earnings results on Wednesday, February 28th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.09). Inari Medical had a positive return on equity of 1.23% and a negative net margin of 0.33%. The company had revenue of $132.10 million during the quarter, compared to analysts’ expectations of $131.82 million. During the same period last year, the firm posted ($0.11) EPS. Inari Medical’s quarterly revenue was up 22.5% compared to the same quarter last year. On average, research analysts predict that Inari Medical, Inc. will post -0.39 EPS for the current fiscal year.

Insider Transactions at Inari Medical

In related news, Director William Hoffman sold 40,000 shares of the business’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $41.13, for a total value of $1,645,200.00. Following the sale, the director now owns 1,003,296 shares in the company, valued at $41,265,564.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director William Hoffman sold 40,000 shares of the business’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $41.13, for a total value of $1,645,200.00. Following the sale, the director now owns 1,003,296 shares in the company, valued at $41,265,564.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Mitch C. Hill sold 6,000 shares of the business’s stock in a transaction on Friday, April 12th. The stock was sold at an average price of $40.96, for a total transaction of $245,760.00. Following the completion of the sale, the chief financial officer now owns 181,294 shares in the company, valued at approximately $7,425,802.24. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 47,451 shares of company stock valued at $1,949,000. 10.60% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

NARI has been the subject of several recent research reports. Needham & Company LLC restated a “buy” rating and set a $72.00 target price on shares of Inari Medical in a research report on Wednesday, March 6th. Piper Sandler downgraded shares of Inari Medical from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $85.00 to $55.00 in a report on Thursday, February 29th. Truist Financial lowered their price target on shares of Inari Medical from $61.00 to $52.00 and set a “hold” rating on the stock in a report on Friday, March 22nd. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $75.00 price target on shares of Inari Medical in a report on Friday, April 12th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $73.71.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.